COMMUNIQUÉS West-GlobeNewswire

Barinthus Bio Reports First Quarter 2026 Financial Results and Updates on Corporate Developments
30/04/2026
Proposed combination with Clywedog Therapeutics Inc. (“Clywedog”) progressing towards closing which will result in a differentiated company focusing on metabolic and autoimmune pipeline assets with multiple important [...]
Royal Columbian Hospital begins patient recruitment in Arch Biopartners’ Phase II trial of LSALT peptide targeting CS-AKI
30/04/2026
TORONTO, April 30, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc . (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that Royal Columbian Hospital (RCH) has begun patient recruitment in the [...]
Kymera Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business Update
30/04/2026
KT-621 (STAT6) parallel Phase 2b trials, BROADEN2 in atopic dermatitis and BREADTH in asthma, ongoing with data expected by mid-2027 and late 2027, respectively FDA granted Fast Track designation to KT-621 for the [...]
BridgeBio to Report First Quarter 2026 Financial Results and Commercial Updates on May 7, 2026 at 4:30 pm ET
30/04/2026
PALO ALTO, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, today [...]
Aurora Spine Corporation Announces Record Fourth Quarter and FY25 Financial Results
30/04/2026
– Q4 revenue surpasses $5 million threshold – –Company to host conference call today, April 30 th at 11am ET/8am PT – NOT FOR DISTRIBUTION IN THE UNITED STATES OR OVER UNITED STATES WIRE SERVICES CARLSBAD, Calif., April [...]
Axogen, Inc. to Participate in the 2026 Bank of America Global Healthcare Conference
30/04/2026
ALACHUA, Fla. and TAMPA, Fla., April 30, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, [...]
Verano Announces $20 Million Share Repurchase Authorization
30/04/2026
CHICAGO, April 30, 2026 (GLOBE NEWSWIRE) -- Verano Holdings Corp. (Cboe CA: VRNO) (OTCQX: VRNO) (“Verano” or the “Company”), a leading multi-state cannabis company, today announced that its Board of Directors has [...]
NetraMark To Open The Market At The Toronto Stock Exchange On May 5, 2026
30/04/2026
TORONTO, April 30, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) , a company developing advanced artificial intelligence solutions for [...]
LENSAR® to Report First Quarter 2026 Results on May 8, 2026
30/04/2026
ORLANDO, Fla., April 30, 2026 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, [...]
AC Immune First Quarter 2026 Financial and Corporate Updates
30/04/2026
AC Immune First Quarter 2026 Financial and Corporate Updates Dosed first subjects in Phase 1 trial of brain-penetrant small molecule NLRP3 inhibitor ACI-19764 with SAD/MAD results in healthy volunteers expected in H2 [...]
EUROAPI_Contrat de liquidité
30/04/2026
Communiqué de presse Paris, 30 avril 2026 Programme de rachat d’actions Réduction de moyen au contrat de liquidité avec Kepler Cheuvreux Par contrat en date du 30 mai 2022, la société EUROAPI (ISIN: FR0014008VX5) a [...]
Orchard Therapeutics Awarded Innovation Passport Designation for OTL-201 in MPS-IIIA
30/04/2026
Designation granted under Innovative Licensing and Access Pathway which aims to accelerate development of, and access to, transformative new medicines in the United Kingdom LONDON, April 30, 2026 (GLOBE NEWSWIRE) -- [...]
EUROAPI_Liquidity Contract
30/04/2026
Press Release Paris 30 avril, 2026 Share buyback program Reduction in the Resources Allocated under the Liquidity Contract with Kepler Cheuvreux By agreement dated 30 May 2022, EUROAPI (ISIN: FR0014008VX5) entrusted [...]
Valneva Announces the Successful Completion of an €84 million Reserved Offering
30/04/2026
Valneva Announces the Successful Completion of an €84 million Reserved Offering Lyon (France), April 30, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) (“ Valneva ” or the “ Company ”), a specialty vaccine [...]
Valneva annonce le succès d’une Offre Réservée d’un montant de 84 millions d’euros
30/04/2026
Lyon (France), le 30 avril 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) (« Valneva » ou la « Société »), société spécialisée dans les vaccins, annonce le succès d’une offre réservée d’un montant de 84 millions [...]
Addex Reports Full Year 2025 Financial Results and Provides Corporate Update
30/04/2026
GABAB PAM chronic cough candidate continued towards clinic after demonstrating robust anti-tussive activity in multiple disease models Continued to reposition dipraglurant mGlu5 NAM for brain injury recovery Entered [...]
Roche to present extensive data showcasing its industry-leading ophthalmology portfolio at ARVO 2026
30/04/2026
New real-world data confirm Vabysmo’s potent retinal drying in nAMD and DME Key data for Susvimo demonstrate its potential to provide lasting disease control through continuous delivery, while reducing treatment burden [...]
Nicox annonce ses résultats financiers 2025 et fait un point sur son activité
30/04/2026
Communiqué de presse Nicox annonce ses résultats financiers 2025 et fait un point sur son activité Chiffre d’affaires de 16,8 millions d’euros (7,9 millions d’euros en 2024) Perte nette significativement réduite à 2,4 [...]
Santhera Proposes Dr. Srishti Gupta as New Member of the Board of Directors
30/04/2026
Ad hoc announcement pursuant to Art. 53 LR. Pratteln, Switzerland, April 30, 2026 – Santhera Pharmaceuticals (SIX: SANN) proposes to elect Dr. Srishti Gupta, MD, MPP, MPhil, as an Independent Director at the upcoming [...]

Pages